FOXO4-DRI (Proxofim)

Description

Overview of FOXO4-DRI

FOXO4-DRI (also referred to as FOXO4-DR) is a synthetic peptide designed for experimental research. 

It is being studied for its intracellular protein interactions associated with cellular senescence in preclinical research models.

Note:FOXO4-DRI is not approved by the U.S Food and Drug Administration for any therapeutic use. It is primarily recognized as a research peptide. We sell it only for lab research purposes. It is not intended for human or animal use.

Chemical Properties

Name	FOXO4-DR
Synonyms	FOXO4-DRI, FOXO4-DR, AFX, AFX1
PubChem CID	167312269
CAS Number	2460055-10-9
Molecular Formula	C228H388N86O64
Molecular Weight	5358.0 g/mol
Classification	Single synthetic peptide
Purity	≥98%
IUPAC Condensed	H-D-Leu-D-Thr-D-Leu-D-Arg-D-Lys-D-Glu-D-Pro-D-Ala-D-Ser-D-Glu-D-Ile-D-Ala-D-Gln-D-Ser-D-Ile-D-Leu-D-Glu-D-Ala-D-Tyr-D-Ser-D-Gln-D-Asn-Gly-D-Trp-D-Ala-D-Asn-D-Arg-D-Arg-D-Ser-Gly-Gly-D-Lys-D-Arg-D-Pro-D-Pro-D-Pro-D-Arg-D-Arg-D-Arg-D-Gln-D-Arg-D-Arg-D-Lys-D-Lys-D-Arg-Gly-OH
Labeling	Research Use Only (RUO)
Storage Temperature	−20 °C (lyophilized)
Solubility	Water-soluble; soluble in DMSO
Safety	Laboratory use only; not for human or animal use
Structure Depiction

Proposed Working Mechanism of FOXO4-DRI

In research settings, FOXO4-DRI has been studied for its potential to disrupt the interaction between FOXO4 and p53 in senescent cells. Disruption of this interaction has been associated with changes in p53 localization and activation of apoptosis-related signaling pathways in preclinical models. 

Preclinical studies have reported that this mechanism may preferentially induce apoptosis in senescent cells under controlled experimental conditions.

This mechanism is studied in experimental research to investigate protein–protein interactions and p53-mediated signaling. It is also studied to investigate mechanisms of senescent cell clearance in experimental models.

Why Choose Purerawz for FOXO4-DRI?

Buy FOXO4-DRI for laboratory research use from our online shop. At Purerawz, we provide high-quality reference materials. Each research compound comes with a Certificate of Analysis for verification of purity and concentration.

Note:

FOXO4-DRI is an investigational compound currently under preclinical investigation and has not been established as safe or effective for any therapeutic use.

Disclaimer

This information is for educational purposes only and not medical advice. Products are for research use only. Research must follow IRB or IACUC guidelines. Verify information independently before purchasing. By ordering, you agree to our Terms and Conditions. If you are not 100% satisfied with the product you received, please contact us at support@purerawz.co

ATTENTION: All our products are for LABORATORY AND RESEARCH PURPOSES ONLY, not for veterinary or human use

Reference Links

• Zhang, C., Xie, Y., Chen, H., Lv, L., Yao, J., Zhang, M., Xia, K., Feng, X., Li, Y., Liang,X., Sun, X., Deng, C., & Liu, G. (2020). FOXO4-DRI alleviates age-related testosterone secretion insufficiency by targeting senescent Leydig cells in aged mice.Aging,12(2), 1272–1284.https://doi.org/10.18632/aging.102682
• Bourgeois, B., Spreitzer, E., Platero-Rochart, D., Paar, M., Zhou, Q., Usluer, S., De Keizer, P. L. J., Burgering, B. M. T., Sánchez-Murcia, P. A., & Madl, T. (2025). The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4-DRI.Nature Communications, 16(1), 5672.https://doi.org/10.1038/s41467-025-60844-9
• PubChem. FOXO4-DRI compound record.https://pubchem.ncbi.nlm.nih.gov/compound/167312269